Wu-Tang Clan's elusive album 'Once Upon a Time in Shaolin,' previously owned by Martin Shkreli, will be available for limited listening sessions at the Museum of Old and New Art in Tasmania, Australia, from June 15-24.
The sole physical copy of Wu-Tang Clan's unreleased album "Once Upon a Time in Shaolin" will be displayed at Australia's Museum of Old and New Art, with private listening sessions available from June 15 to June 24. The album, considered the world's rarest, was sold to satisfy Martin Shkreli's court debts and later bought by cryptocurrency collective PleasrDAO for $4 million.
The Museum of Old and New Art in Hobart, Tasmania, will host private listening events for the rare Wu-Tang Clan album "Once Upon a Time in Shaolin," which was originally not to be heard by the public until 2103. The album, caught up in various ownership controversies, will be partially played from June 15 to June 24.
The Wu-Tang Clan's rare album "Once Upon a Time in Shaolin" will be publicly played for the first time at Australia's Museum of Old and New Art (MONA) during the Namedropping exhibition from June 15-24. The album, previously owned by Martin Shkreli and now by digital art collective Pleasr, will be featured in 30-minute listening events and displayed in its silver box.
The sole copy of Wu-Tang Clan's album "Once Upon a Time in Shaolin" will be publicly played for the first time at the Museum of Old and New Art in Tasmania. The album, bought by Martin Shkreli for $2 million and later seized by the US government, will be part of the "Namedropping" exhibition from June 15-24, 2024.
The attorney for Eric and Donald Trump Jr. expressed outrage at the New York Attorney General's attempt to compare their case to that of Martin Shkreli, citing it as a reckless use of power in her pursuit to ban the Trump sons from the real estate business for five years. The attorney accused the Attorney General of interfering in free markets for political gain, placing every New York business transaction at risk.
Martin Shkreli, infamously known as "pharma bro," has had his lifetime ban from the pharmaceutical industry upheld by a US court. The ban was imposed due to his antitrust violations, including the astronomical price increase of a life-saving drug. Shkreli's appeal was rejected, and he was ordered to repay $64.6m. The court emphasized the likelihood of his past misconduct recurring and the life-threatening nature of its results. Shkreli's lawyer indicated the possibility of a further appeal, while the FTC hailed the decision as a win for consumers seeking affordable medication.
New York Attorney General Letitia James is seeking a lifetime ban for former President Donald Trump from the state's real estate industry, citing a recent appeals court ruling against Martin Shkreli as supporting precedent. The ruling upheld a lower court's lifetime ban on Shkreli from the pharmaceuticals industry due to antitrust violations. James is currently suing Trump for alleged business fraud and is pushing for a lifetime ban, along with fines, for him and his sons. The legal connection between Shkreli and Trump stems from their controversial online behavior and real-world actions, despite their initial public clashes.
New York Attorney General Letitia James cited Martin Shkreli's lifetime ban from the pharmaceutical industry to support her case against former President Donald Trump, seeking to block him from the real estate industry for fraudulently inflating his assets. The Second Circuit upheld Shkreli's ban due to his monopolistic behavior, and James wants a similar ban for Trump and his associates, along with disgorgement of ill-gotten gains. The attorney general's office invoked a federal judge's ruling against Shkreli, citing the same statute used against Trump, and the judge is expected to issue a ruling before the end of the month.
A federal appeals court has upheld a lifetime ban on Martin Shkreli from the pharmaceutical industry and ordered him to pay up to $64.6 million in disgorged profits for blocking competition to the drug Daraprim. The ruling stems from Shkreli's monopolistic behavior in raising the price of Daraprim by over 4,000% overnight while serving as CEO of Turing Pharmaceuticals AG. The ban and financial penalty were imposed for violations of antitrust laws preventing generic drug makers from accessing Daraprim for testing. Shkreli's appeal against the ban and monetary penalty was rejected by the court, which found his illegal scheme to be "egregious, deliberate, repetitive, long-running, and ultimately dangerous."
Martin Shkreli, the infamous "Pharma Bro" who served time in prison for securities fraud and price gouging a life-saving drug, is lobbying Elon Musk to regain access to his suspended X (formerly Twitter) account. Shkreli claims that Musk's actions contradict his free speech mantra and accuses him of favoring profits over principles. Shkreli believes he needs an active X account for his new entrepreneurial venture involving Artificial Intelligence (AI). Despite multiple attempts at outreach, Shkreli has not heard from Musk. He also points out that other controversial figures, such as Laura Loomer and Kanye West, have regained access to their accounts through Musk.